Edward Dyson

Partner

Londra

Ed counsels public and pre-IPO private companies, investors, entrepreneurs and underwriters on London Stock Exchange, Nasdaq and NYSE capital markets transactions.

He also regularly advises on domestic and cross-border public and private M&A deals, strategic ventures, venture capital and growth equity financings, direct listings/introductions, block trades, demergers/spin-outs, dual-listings, reverse mergers, de-SPACs/reverse takeovers, class and related party transactions, share buy-backs, transfers of listing segment and other corporate matters.

His broad industry experience includes working with companies in the energy, financial services, healthcare and life sciences, logistics, retail, media, natural resources and technology sectors.

  • IPOs / Follow-ons:

    • Tiziana Life Sciences plc on its AIM to Main Market migration, Nasdaq dual-listing, Bermudan redomiciliation and various global follow-on securities offerings
    • Codex Acquisitions plc, URA Holdings plc and Hamak Gold Limited on their Main Market IPOs and Standard listings
    • Heptares Therapeutics Limited, as a major shareholder, on the Nasdaq IPO of Centessa Pharmaceuticals plc
    • Hummingbird Ventures, as a major shareholder, on the Main Market IPO and standard listing of Deliveroo plc
    • Endava plc on its NYSE IPO
    • Renalytix AI plc on its demerger, AIM IPO and subsequent Nasdaq dual-listing
    • the underwriters on the Nasdaq IPOs of Compass Pathways plc, Horizon Discovery plc (aborted), Bicycle Therapeutics plc, Kymab Limited (aborted) and Mereo BioPharma Group plc (aborted)
    • Autolus Therapeutics plc on its Nasdaq IPO and various follow-on securities offerings
    • Scancell Holdings plc on various AIM follow-on securities offerings
    • OKYO Pharma Limited on its Main Market IPO and Standard listing, and associated placing and warrant issuance
    • Realm Therapeutics plc on its direct dual-listing on Nasdaq and subsequent AIM delisting
    • Misys plc on its aborted Main Market IPO and Premium listing
    • B&M European Value Retail S.A. (B&M Stores) on its Main Market IPO and Premium listing
    • the underwriters on the Main Market IPO and Premium listing of Metro Bank plc

    De-SPACs / M&A:

    • VNV Global, as a major shareholder, on the Nasdaq de-SPACs of Swvl with Queen's Gambit Growth Capital and Gett with Rosecliff Acquisition Corp I
    • Kinnevik, as a major shareholder, on the Nasdaq de-SPAC of Babylon Health with Alkuri Global Acquisition
    • Kistos plc on its AIM IPO and subsequent reverse takeover of Tulip, associated placing, PrimaryBid offer, subscription and Norwegian listed bond offering
    • Realm Therapeutics plc on its acquisition by Essa Pharma Inc. by way of scheme of arrangement
    • RockRose Energy plc on its readmission to the Main Market and Standard listing following the reverse takeover of certain North Sea interests from Marathon Oil
    • National World plc on its Main Market IPO and Standard listing, and subsequent reverse takeover of JPI Media and associated convertible loan note offering
    • MightyHive Inc. on its acquisition by S4 Capital plc
    • Just Retirement Group plc on its standby underwritten follow-on offering, associated merger with Partnership Assurance Group plc and Main Market introduction and Premium listing of the combined entity, Just Group plc

    Private Capital / Strategic Transactions:

    • FOMTECH Limited (Floww) on its Series B financing and strategic partnership with London Stock Exchange Group to create the Global Private Capital Market
    • Metro Africa Xpress Inc. on its Series B financing
    • the financial advisers on a convertible loan note financing by Hawkwing plc
    • Sosei Heptares Corporation on its strategic collaboration and licensing agreement with Neurocrine Biosciences Inc. to develop novel muscarinic receptor agonists for schizophrenia and other neuropsychiatric disorders

    Please note: Ed's experience includes that prior to joining Orrick.